Global Colorectal Cancer Therapeutics Market Report and Forecast 2024-2032

Global Colorectal Cancer Therapeutics Market Outlook

The global colorectal cancer therapeutics market size attained a value of USD 15.75 billion in 2023 driven by robust healthcare infrastructure, increased treatment rates, inflated pharmaceutical prices, launch of new medicinal products. The market is anticipated to grow at a CAGR of 6.4% during the forecast period of 2024-2032 to attain a value of USD 27.52 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

News and Developments in the Market

In June 2023, a study was published in The New England Journal of Medicine, which discovered that immune checkpoint inhibitor medication might be particularly beneficial in persons with a specific kind of rectal cancer. It may be sufficiently effective in patients with this type of cancer to avoid the need for additional treatments like surgery.

Participants in the trial had a very particular type of rectal cancer classified as mismatch repair-deficient and locally advanced rectal cancer. This form of cancer could be adequately treated with immunotherapy.

An immune checkpoint inhibitor known as a PD-1 inhibitor was utilised by the researchers, which would prevent cancer cells from destroying the immune system. The study comprised 14 adults with mismatch repair-deficient rectal cancer in stage 2 or stage 3. Dostarlimab, a PD-1 inhibitor, was administered intravenously every three weeks for a period of six months to participants. The participants favourably received this treatment.

By the end of the experiment, none of them required chemoradiotherapy or additional ssurgery, and none of the participants had any signs of tumours. Participants have now completed at least six months of follow-up. Such discoveries are expected to aid the colorectal cancer therapeutics market growth.

In November 2021, Natco Pharma introduced a unique fixed-dose combination of Trifluridine and Tipiracil. This combination is used for the treatment of advanced cancer, especially colorectal and gastric cancer. The medicine was first offered by Natco in a bottle of 20 tablets under the brand name Tipanat. In order to treat advanced colorectal and gastric cancer, a unique antineoplastic nucleoside analogue called Tipanat is used.

Around 1,25,000 new cancer cases are reported annually in India. Tipanat is important in extending survival and maintaining the quality of life in the final stages of treatment, which is an unmet medical need at the moment.

In September 2021, a non-profit cancer research initiative called Count Me In, invited all the patients with colorectal cancer across the United States and Canada. This included patients who were either suffering or have recovered and became cancer-free. They were invited to participate in its research and help drive discoveries related to this disease.

A better understanding of the disease and improved treatments for colorectal cancer would be made possible by the de-identified data collected from the patients who had participated in the project. Thus, increasing research activities by major companies will likely increase the colorectal cancer therapeutics market share.

Prevalence of Colorectal Cancer, Ageing Population, and Government Initiatives are the Major Factors Propelling the Growth of the Colorectal Cancer Therapeutics Market

Colorectal cancer, also referred to as rectal cancer, colon cancer, or bowel cancer, is brought on by the development of cancerous cells in the colon or rectum, which are parts of the large intestine. These cells can expand to other human organs and often act in a malignant manner. Blood in the stools, weight loss, altered bowel habits, and fatigue are the few symptoms of colorectal cancer.

• A key driver aiding the colorectal cancer therapeutics market expansion is the rising incidence of the colorectal cancer worldwide.

• As there are more cancer cases, there is a rising need for efficient and cutting-edge therapies, which is driving the development of the market under study.

• The growing ageing population and increasing public awareness of this condition are driving the market growth.

• The development of the market is anticipated to be fuelled by a number of government initiatives to offer better and more inexpensive treatments and favourable reimbursement rules.

Availability of Several Treatment Options, Launch of New Therapeutics, Research and Development Activities Likely to Provide Significant Opportunities to the Market

Availability of Treatment Options

The global market for colorectal cancer therapeutics has a good prospect due to the accessibility of treatment choices and the development of more tailored medications.

Increasing Acceptance of Advanced Therapies

The rising consumer acceptance of cutting-edge treatments, including Stivarga (regorafenib), Erbitux (cetuximab), and Avastin (bevacizumab) are expected to aid the colorectal cancer therapeutics market development.

Launch of New Therapeutics

The major market participants would progress and introduce novel therapies, clinical trials, and other studies, which will have a favourable effect on the market.

Increasing Research and Development Activities

The colorectal cancer therapeutics market forecast is likely to see a rise in research and development activities, along with a better understanding of colorectal malignancies and associated symptoms.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

High Cost, Side Effects, and Stringent Guidelines May Pose as Challenges for the Colorectal Cancer Therapeutics Market

High Cost for Drug Development

High development costs for oncology drugs could slow the expansion of the colorectal cancer therapeutics market because consumers would not be able to afford them. Additionally, because of the unpredictability and regional variation in the approval, clinical acceptance, and inclusion of costly new pharmaceuticals, it is difficult for insurance companies to appropriately calculate policy premiums due to the skyrocketing drug prices.

Side Effects of Drugs

Throughout the forecast period, various side effects of drugs are anticipated to restrain the colorectal cancer therapeutics market demand. For instance, chemotherapy medication specifically targets rapidly dividing cells, which makes them significantly effective against cancer cells. However, other cells in the body also keep getting divided rapidly, including those in hair follicles and the lining of the mouth and intestines. Chemotherapy can also impact these cells, which may have negative side effects.

Stringent Guidelines

Various stringent guidelines for the approval of new treatments, such as FDA approvals, may hamper the market growth globally.

Colorectal Cancer Therapeutics Market Analysis

Based on therapy, the market is categorised into immunotherapy, targeted therapy, and chemotherapy, among others. The market for colorectal cancer therapeutics, based on cancer type, can be segmented into colorectal adenocarcinoma and gastrointestinal carcinoid tumours, among others. The several distribution channels of the market are retail pharmacies, hospital pharmacies, and online channels, among others. The regional markets for the colorectal cancer therapeutics can be divided into Europe, North America, the Asia Pacific, the Middle East and Africa and Latin America.

The analysis of the major players of the global colorectal cancer therapeutics market is examined in a nutshell through this report. Apart from this, this report also covers the competitive landscape and newest developments like mergers, expansion plans, acquisitions and investments.

• Genentech, Inc.

• Eli Lilly and Company

• Bayer AG

• Amgen Inc.

• F. Hoffmann-La Roche Ltd.

• Sanofi SA

• Others

Targeted Therapy, Immunotherapy, and Chemotherapy are the Major Therapies Available for Colorectal Cancer

Due to its sensitivity targeting cancer cells while minimising harm to off-target cells, targeted therapy is favoured. It consists of toxin delivery agents, angiogenesis inhibitors, apoptosis inducers, hormone treatments, and gene expression modulators.

The frequently recommended cancer treatment is chemotherapy. It employs specific medications to eradicate cancer cells or prevent their growth and spread to other bodily regions. Thus, chemotherapy is expected to act as one of the major colorectal cancer therapeutics market drivers.

The use of drugs in immunotherapy aids the immune system of a patient to identify and eliminate cancer cells. It helps individuals suffering from advanced colorectal cancer. Immunotherapy has also demonstrated promising efficacies, along with good tolerance in gastrointestinal (GI)-related cancers, such as gastro-oesophageal cancer and hepatocellular carcinoma.

Colorectal Adenocarcinoma and Gastrointestinal Carcinoid Tumours are the Major Types in Colorectal Cancer Therapeutics Market

Colorectal adenocarcinoma is a cancer that occurs in the large intestine, which is made of rectum and colon and is referred to as colorectal. Adenocarcinomas comprise of most of colorectal cancers. Although they seldom affect the colon, these tumours begin in the muscles of the digestive tract. Although many of them do develop into cancer, they can initially be benign (non-cancerous).

Gastrointestinal carcinoid tumours are a form of cancer that can be developed in the GI tract. They are most frequently found in appendix, small intestine, and rectum. Oncogenes or tumour suppressor genes frequently undergo random changes (mutations) that result in carcinoid tumours.

Hospital Pharmacies, Retail Pharmacies, and Online are the Several Distribution Channels in Colorectal Cancer Therapeutics Market Research

The growth of the hospital segment can be attributed to the growing number of patients visiting hospitals for cancer diagnosis and treatment and the favourable reimbursement scenario, especially in the developed markets.

Retail pharmacies are expanding due to the growing instances of prescriptions re-fillings. Also, retail pharmacies are able to provide more facilities efficiently.

Due to the rising popularity of online pharmacy services, which are becoming more and more popular due to their simplicity and convenience, the online segment is anticipated to experience substantial growth.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

North America to be a Leading Regional Market for Colorectal Cancer Therapeutics Market Report

Due to the increasing prevalence of colorectal cancer, growing geriatric population, and strong healthcare infrastructure in the region, North America is anticipated to dominate the market for colorectal cancer therapeutics. Due to the growing prevalence of colorectal cancer, increased treatment rates, inflated pharmaceutical prices, and the availability of advanced treatments in the country, the United States is predicted to control the majority of the market in North America.

By 2030, colorectal cancer will surpass lung cancer as the leading cause of cancer mortality in those between the ages of 20 and 49. It is among the top reasons of death in the United States. According to a National Library of Medicine publication, 0.16 million additional CRC cases are anticipated in the United States in 2020 and will total 0.21 million by 2040.

According to the colorectal cancer therapeutics market research, the demand for colorectal cancer therapies is likely to rise in North America, therefore increasing the market demand globally.

Asia Pacific to Witness Significant Growth in the Coming Years

On the other hand, the market in the Asia Pacific region is expected to witness a significant growth rate in the forecast period owing to the availability and accessibility of effective treatment options, increasing disposable incomes, unmet clinical needs of patients, and increasing population in India and China. China is anticipated to have a 64 percent increase in colorectal cancer cases from 0.56 million in 2020 to 0.91 million in 2040.

In addition, Japan is expected to grow rapidly relative to other important markets. Japan is expected to experience 1,48,500 new cases of CRC, 60,000 CRC deaths, and 0.16 million incident cases during the next 20 years. Therefore, the growing cases of cancer are improving the global colorectal cancer therapeutics market value.

Competitive Landscape

Genentech, Inc. is a biotechnology company committed to pioneering research to find and create treatments for people with life-threatening diseases. The first cancer targeted antibody and the first treatment for primary progressive multiple sclerosis are the two of its ground-breaking discoveries.

Eli Lilly and Company is a pharmaceutical manufacturing company. The company is involved in the global research, development, production, marketing, and sales of pharmaceutical goods. Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio are some of its oncology products.

Bayer AG is a life science company working on agriculture and healthcare industries. Bayer currently markets treatments for prostate, colorectal, follicular lymphoma, kidney, liver, and thyroid cancers and a precision treatment for NTRK fusions, which are found in more than 25 solid tumour types, including paediatrics cancers.

Amgen Inc. is one of the global biotechnology firms. It focuses on six therapeutic fields: inflammation, nephrology, neurology, cancer, and cardiovascular disease. The majority of Amgen's medications treat conditions for which there are few effective treatments, or they offer an effective alternative to those that are currently on the market.

F. Hoffmann-La Roche Ltd. (Roche) is a biotechnology corporation which creates medications and diagnostic tools to combat serious illnesses. For cancer treatment and other autoimmune illnesses, it offers medications.

Roche has been working on drugs that will transform oncology care. The company is investing more money than ever to provide individuals with cancer with individualised immunotherapy. These growing investments are acting as colorectal cancer therapeutics market trends.

Sanofi SA is a France-based healthcare organisation. The company focuses on patient needs and works to research, manufacture, and sell therapeutic solutions. Pharmaceuticals, vaccines and consumer healthcare (CHC), make up its three operating segments. The medications cover immunology, diabetes, cardiology, oncology, rare disorders, multiple sclerosis/neurology, and oncology.

Key Highlights of the Report